Parkev Tatevosian, CFA on $LLY (Nov 10, 2026)
Eli Lilly is a buy-and-hold-forever recommendation because its decades of serial successes, not just weight-loss treatments, make the current success non-fleeting; with the stock at $1,366 versus his $1,662 valuation, he owns shares and wants to add more.
Jump to any passage
What you see here is my valuation, and my discounted cash flow model for the first stock I'm going to mention that you can buy now and hold forever, which is Eli Lilly.
Eli Lilly is a pharmaceutical company with decades of experience in researching and developing treatments that generate billions of dollars in sales and profits. Currently, the company is benefiting from its recent success in weight loss treatments, but the company has a history of one success after another.
That's why I feel confident in recommending this stock and rating it as one you can buy now and hold for a very long time, because it's not a fleeting success. Weight loss treatments are not the only thing the company has done in its decades-long history.
Currently, Eli Lilly stock is trading at $1,366 per share, and I value the company at $1,662. I like this company so much that I have its shares in my portfolio and I am interested in adding more.
What this channel has said about $LLY
Parkev Tatevosian, CFA has 3 calls on this stock; only the adjacent ones are shown.